Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.

Humans Glioblastoma / diagnostic imaging Ficus Brain Neoplasms / diagnostic imaging Nuclear Medicine Prospective Studies Australia Positron-Emission Tomography / methods Tyrosine Magnetic Resonance Imaging
Clinical trials Credentialing FET PET Glioblastoma Inter-observer

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 27 05 2023
accepted: 28 07 2023
medline: 30 10 2023
pubmed: 11 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

The O-(2-[ Sites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBR Data was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBR The FIG study credentialing program has increased expertise across study sites. TBR

Identifiants

DOI: 10.1007/s00259-023-06371-5 PMID: 37563351 PMC: PMC10611835
pubmed: 37563351
doi: 10.1007/s00259-023-06371-5
pii: 10.1007/s00259-023-06371-5
pmc: PMC10611835
doi:

Substances chimiques

Tyrosine 42HK56048U

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3970-3981

Subventions

Organisme : Department of Health and Aged Care, Australian Government
ID : MRF1152501
Organisme : Department of Health and Aged Care, Australian Government
ID : MRF9500003
Organisme : National Health and Medical Research Council
ID : 1177837

Informations de copyright

© 2023. The Author(s).

Références

Neurology. 2015 Feb 17;84(7):710-9
pubmed: 25609769
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Curr Oncol Rep. 2021 Feb 18;23(3):34
pubmed: 33599882
Neurosurgery. 2010 Nov;67(5):1329-34
pubmed: 20871451
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1889-1901
pubmed: 31203420
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):373-381
pubmed: 27554774
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):443-451
pubmed: 29043400
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1458-1467
pubmed: 31919633
Radiother Oncol. 2011 Apr;99(1):44-8
pubmed: 21458093
Brain. 2005 Mar;128(Pt 3):678-87
pubmed: 15689365
Neuro Oncol. 2021 Jun 1;23(6):881-893
pubmed: 33538838
Int J Mol Sci. 2022 Jun 17;23(12):
pubmed: 35743228
Radiat Oncol. 2008 Dec 24;3:44
pubmed: 19108742
Eur Radiol. 2015 Oct;25(10):3017-24
pubmed: 25813014
J Neurooncol. 2018 Sep;139(3):721-730
pubmed: 29948765
BMJ Open. 2023 Aug 4;13(8):e071327
pubmed: 37541751
J Nucl Med. 2015 Jan;56(1):9-15
pubmed: 25537990
J Nucl Med. 2013 Feb;54(2):229-35
pubmed: 23232275
Neuro Oncol. 2019 May 6;21(5):585-595
pubmed: 30615138
Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95
pubmed: 25411133
Sci Rep. 2021 Oct 21;11(1):20828
pubmed: 34675225
EJNMMI Res. 2017 Dec;7(1):48
pubmed: 28560582
Radiother Oncol. 2016 Aug;120(2):241-7
pubmed: 27378734
Clin Nucl Med. 2011 Oct;36(10):841-7
pubmed: 21892031
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2377-2386
pubmed: 29982845
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):103-112
pubmed: 26363903
J Nucl Med. 2012 Jul;53(7):1048-57
pubmed: 22645298
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Radiother Oncol. 2019 Jan;130:121-131
pubmed: 30219612
PLoS One. 2018 Apr 13;13(4):e0195798
pubmed: 29652908
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
BMC Med Imaging. 2015 Aug 12;15:29
pubmed: 26263899
Nucl Med Biol. 2009 Oct;36(7):779-87
pubmed: 19720290
J Nucl Med. 2021 Jul 1;62(7):918-925
pubmed: 33158907
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1956-1965
pubmed: 33241456
Neurosurgery. 2017 Sep 1;81(3):397-415
pubmed: 28486641
Neuroimage Clin. 2019;22:101727
pubmed: 30825711
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1100-6
pubmed: 24161427
Strahlenther Onkol. 2012 Apr;188(4):334-9
pubmed: 22349712
EJNMMI Phys. 2022 Feb 5;9(1):9
pubmed: 35122529
PLoS One. 2016 Oct 25;11(10):e0164891
pubmed: 27780224
Chin Clin Oncol. 2017 Aug;6(4):40
pubmed: 28841802
Cancers (Basel). 2022 Jul 08;14(14):
pubmed: 35884396
Tomography. 2022 Aug 16;8(4):2030-2041
pubmed: 36006068

Auteurs

Nathaniel Barry (N)

School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia. Nathaniel.barry@research.uwa.edu.au.
Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia. Nathaniel.barry@research.uwa.edu.au.
ORCID: 0000-0002-9009-5909

Roslyn J Francis (RJ)

Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, WA, Australia.

Martin A Ebert (MA)

School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia.
Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, WA, Australia.
Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

Eng-Siew Koh (ES)

Department of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centres, Liverpool, NSW, Australia.
South Western Sydney Clinical School, UNSW Medicine, University of New South Wales, Liverpool, NSW, Australia.

Pejman Rowshanfarzad (P)

School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia.

Ghulam Mubashar Hassan (GM)

School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.

Jake Kendrick (J)

School of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
Centre for Advanced Technologies in Cancer Research (CATCR), WA, Perth, Australia.

Hui K Gan (HK)

Department of Medical Oncology, Austin Hospital, Melbourne, VIC, Australia.
Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.

Sze T Lee (ST)

Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.

Eddie Lau (E)

Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.
Department of Radiology, Austin Health, Melbourne, VIC, Australia.
Department of Radiology, University of Melbourne, Melbourne, VIC, Australia.

Bradford A Moffat (BA)

Department of Radiology, University of Melbourne, Melbourne, VIC, Australia.

Greg Fitt (G)

Department of Radiology, Austin Health, Melbourne, VIC, Australia.

Alisha Moore (A)

Trans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.

Paul Thomas (P)

Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia.

David A Pattison (DA)

Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia.

Tim Akhurst (T)

Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
The Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia.

Ramin Alipour (R)

Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
The Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia.

Elizabeth L Thomas (EL)

Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

Edward Hsiao (E)

Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia.

Geoffrey P Schembri (GP)

Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia.

Peter Lin (P)

South Western Sydney Clinical School, UNSW Medicine, University of New South Wales, Liverpool, NSW, Australia.
Department of Nuclear Medicine, Liverpool Hospital, Liverpool, NSW, Australia.

Tam Ly (T)

Department of Nuclear Medicine, Liverpool Hospital, Liverpool, NSW, Australia.

June Yap (J)

Department of Nuclear Medicine, Liverpool Hospital, Liverpool, NSW, Australia.

Ian Kirkwood (I)

Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia.

Wilson Vallat (W)

Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.

Shahroz Khan (S)

Department of Nuclear Medicine, Canberra Hospital, Woden, ACT, Australia.

Dayanethee Krishna (D)

Department of Nuclear Medicine, Canberra Hospital, Woden, ACT, Australia.

Stanley Ngai (S)

Department of Nuclear Medicine, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.

Chris Yu (C)

Department of Nuclear Medicine, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.

Scott Beuzeville (S)

Department of Nuclear Medicine, St George Hospital, Kogarah, NSW, Australia.

Tow C Yeow (TC)

Department of Nuclear Medicine, St George Hospital, Kogarah, NSW, Australia.

Dale Bailey (D)

Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia.
Faculty of Medicine 7 Health, University of Sydney, Sydney, NSW, Australia.

Olivia Cook (O)

Trans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.

Angela Whitehead (A)

Trans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.

Rachael Dykyj (R)

Trans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.

Alana Rossi (A)

Trans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.

Andrew Grose (A)

Trans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.

Andrew M Scott (AM)

Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Delineation and agreement of FET PET...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Delineation and agreement of FET PET...
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Rosanae › Rosales › Moraceae › Ficus › Delineation and agreement of FET PET...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Delineation and agreement of FET PET...
questionsmedicales.fr › Professions de santé › Médecine › Radiologie › Médecine nucléaire › Delineation and agreement of FET PET...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Delineation and agreement of FET PET...
questionsmedicales.fr › Régions géographiques › Océanie › Australasie › Australie › Delineation and agreement of FET PET...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Delineation and agreement of FET PET...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés cycliques › Acides aminés aromatiques › Tyrosine › Delineation and agreement of FET PET...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Delineation and agreement of FET PET...